DexCom, Inc.
Financials
Valuation Metrics
DexCom, Inc.'s Market Cap is $33.72B. At end of 2025 it was $25.67B. Ranked #430 of 3,121 in US market (top 14%), #126 of 1,463 on NASDAQ (top 9%), #26 of 205 in Health Care Equipment & Services (top 13%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $33.72B | US#430/3,121 Sec#26/205 |
| Revenue | $4.97B | US#892/3,121 Sec#51/205 |
| Net Income | $1000M | US#547/3,121 Sec#31/205 |
| Total Assets | $6.46B | US#1,266/3,121 Sec#56/205 |
| Net Assets | $2.62B | US#1,063/3,121 Sec#55/205 |
| Employees | 11,000 | US#815/3,121 Sec#62/205 |
| Value | ||
| P/E | 33.73x | US#1,667/3,121 Sec#68/205 |
| P/B | 12.86x | US#2,693/3,121 Sec#173/205 |
| PEG | 0.45x | US#568/3,121 Sec#21/205 |
| P/S | 6.78x | US#2,505/3,121 Sec#164/205 |
| EV/EBITDA | 21.81x | US#1,960/3,121 Sec#91/205 |
| FCF Yield | 4.17% | US#1,575/3,121 Sec#82/205 |
| Profitability | ||
| ROE | 38.14% | US#192/3,121 Sec#10/205 |
| ROA | 15.49% | US#210/3,121 Sec#9/205 |
| Op. Margin | 22.92% | US#775/3,121 Sec#19/205 |
| Revenue Growth | 15.54% | US#890/3,121 Sec#60/205 |
| Earnings Growth | 74.93% | US#384/3,121 Sec#15/205 |
| Financial Health | ||
| Debt Ratio | 146.25% | US#1,476/3,121 Sec#133/205 |
| Total Debt | $1.40B | US#1,370/3,121 Sec#71/205 |
| FCF | $1.41B | US#472/3,121 Sec#31/205 |
| Cash | $1.10B | US#627/3,121 Sec#33/205 |
| Current Ratio | 1.73x | US#1,444/3,121 Sec#125/205 |
| Net Debt/EBITDA | 0.19x | US#663/3,121 Sec#46/205 |
| Performance | ||
| 1Y Return | 17.90% | US#1,316/3,121 Sec#100/205 |
| 1M Return | -0.60% | US#1,196/3,121 Sec#106/205 |
| From 52W High | -3.50% | US#310/3,121 Sec#36/205 |
| 1Y MDD | -22.83% | US#905/3,121 Sec#22/205 |
| Trading | ||
| Volume | 4,791,002 shares | US#819/3,121 Sec#45/205 |
| Trading Value | $426M | US#518/3,121 Sec#46/205 |
| Per Share | ||
| EPS | $2.65 | US#1,152/3,121 Sec#60/205 |
| BPS | $6.95 | US#2,098/3,121 Sec#124/205 |
Company Info
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.